{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-003288","form_type":"8-K","ticker":"PAYS","cik":"0001496443","company_name":"Paysign, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.457009+00:00","generated_at":"2026-05-22T04:01:32.638927+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Paysign Q1 2025 revenue up 41% to $18.6M, net income $2.59M; raises full-year guidance","bullets":["Total revenues $18.60M (+41% YoY); net income $2.59M ($0.05 diluted EPS) vs $309K ($0.01) in Q1 2024.","Adjusted EBITDA $4.96M (+193.3%); pharma patient affordability revenue surged 260.8% to 46.3% of revenue.","Added 14 net patient affordability programs (total 90); plasma revenue fell 9.2%, center count 484.","FY2025 guidance raised: revenue $72-74M, net income $6-7M ($0.10-$0.12 EPS), Adj. EBITDA $16-17M.","Q2 2025 revenue guided $18.5-19.0M; Gamma acquisition expected to generate $4-5M annual cash cost savings."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-003288","json":"https://secwatch.observer/filing/0001683168-25-003288.json","markdown":"https://secwatch.observer/filing/0001683168-25-003288.md","text":"https://secwatch.observer/filing/0001683168-25-003288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1496443/000168316825003288/0001683168-25-003288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1496443/000168316825003288/paysign_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:01:32.638927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}